Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Interleukin–based therapy for Age-associated dementia and Alzheimer’s disease (AD): IL-17 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 14/June/2015, 9.57 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Significance:
Given that: (1) in 2006, 26.6 million people worldwide’re afflicted by Alzheimer’s disease; (2) the number of cases diagnosed with Alzheimer’s disease may increase from 26.6 million people in 2006 to 106.4 million in 2050 worldwide; (3) Alzheimer’s disease is the forth leading cause of death in US in the elderly; (4) Alzheimer’s disease is the third most costly disease to treat only after cancer and coronary heart disease; and (5) US$80–100 billion spent in US in caring for patients diagnosed with Alzheimer’s disease, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; and (ii) a side-effect-free natural product-based drug.
This study suggests, for the first time, that IL-17, by decreasing the expression of its target gene, it may: (1) increase the expression of AGE receptor 1 (AGER1); (2) increase the expression of longevity-promoting gene Sirtuin-1; and (3) decrease advanced glycation end products (AGEs). Thus, pharmacological formulations encompassing “IL-17 activators” can be used to decrease ageing and increase the life-span of an individual.
Undisclosed information: How IL-17 increases the expression of AGER1
Web: http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation